Published in Circulation on May 07, 2002
Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice. J Clin Invest (2010) 1.78
The role of mineralocorticoid receptor expression in brain remodeling after cerebral ischemia. Endocrinology (2008) 1.61
Mineralocorticoid receptors in vascular function and disease. Mol Cell Endocrinol (2011) 1.38
Aldosterone: effects on the kidney and cardiovascular system. Nat Rev Nephrol (2010) 1.35
Aldosterone does not mediate angiotensin II-induced atherosclerosis and abdominal aortic aneurysms. Br J Pharmacol (2005) 1.10
Effect of aldosterone and mineralocorticoid receptor blockade on vascular inflammation. Heart Fail Rev (2005) 1.05
Aldosterone increases early atherosclerosis and promotes plaque inflammation through a placental growth factor-dependent mechanism. J Am Heart Assoc (2013) 1.02
Aldosterone: a forgotten mediator of the relationship between psychological stress and heart disease. Neurosci Biobehav Rev (2009) 0.99
Mineralocorticoid receptors modulate vascular endothelial function in human obesity. Clin Sci (Lond) (2013) 0.97
Role of cellular mechanics in the function and life span of vascular endothelium. Pflugers Arch (2011) 0.96
Eplerenone suppresses aldosterone/ salt-induced expression of NOX-4. J Renin Angiotensin Aldosterone Syst (2011) 0.94
Endothelial cell swelling by aldosterone. J Membr Biol (2003) 0.93
Aldosterone blockade in cardiovascular disease. Heart (2004) 0.92
Aldosterone affects blood flow and vascular tone regulated by endothelium-derived NO: therapeutic implications. Br J Pharmacol (2013) 0.92
Mineralocorticoid receptors in vascular disease: connecting molecular pathways to clinical implications. Curr Atheroscler Rep (2013) 0.90
Aldosterone induces mesangial cell apoptosis both in vivo and in vitro. Am J Physiol Renal Physiol (2008) 0.89
Detection of macrophages via paramagnetic vesicles incorporating oxidatively tailored cholesterol ester: an approach for atherosclerosis imaging. Nanomedicine (Lond) (2010) 0.87
Smooth muscle cell mineralocorticoid receptors: role in vascular function and contribution to cardiovascular disease. Pflugers Arch (2013) 0.86
Spironolactone lowers portal hypertension by inhibiting liver fibrosis, ROCK-2 activity and activating NO/PKG pathway in the bile-duct-ligated rat. PLoS One (2012) 0.86
Renal denervation attenuates progression of atherosclerosis in apolipoprotein E-deficient mice independent of blood pressure lowering. Hypertension (2015) 0.84
Spironolactone improves endothelial dysfunction in streptozotocin-induced diabetic rats. Naunyn Schmiedebergs Arch Pharmacol (2014) 0.81
Aldosterone and the mineralocorticoid receptor in the cerebral circulation and stroke. Exp Transl Stroke Med (2012) 0.81
Pathophysiology of heart failure following myocardial infarction. Heart (2005) 0.81
Mineralocorticoid receptor antagonists and endothelial function. Curr Opin Investig Drugs (2008) 0.80
The role of mineralocorticoid receptor antagonists (MRAs) in very old patients with heart failure. Heart Fail Rev (2012) 0.80
Update on RAAS Modulation for the Treatment of Diabetic Cardiovascular Disease. J Diabetes Res (2016) 0.78
Eplerenone suppresses salt-induced vascular endothelial growth factor expression in the kidney. Kidney Blood Press Res (2010) 0.77
Effect of Selective Mineralocorticoid Receptor Blockade on Flow-Mediated Dilation and Insulin Resistance in Older Adults with Metabolic Syndrome. Metab Syndr Relat Disord (2015) 0.76
Acute effect of mineralocorticoid receptor antagonism on vascular function in healthy older adults. Exp Gerontol (2015) 0.76
Role of mineralocorticoid receptors in arterial stiffness in human aging. Exp Gerontol (2013) 0.76
The alpha linolenic acid content of flaxseed is associated with an induction of adipose leptin expression. Lipids (2011) 0.76
The role of aldosterone blockade in patients with heart failure. Heart Fail Rev (2005) 0.75
High Dietary Sodium Intake Assessed by Estimated 24-h Urinary Sodium Excretion Is Associated with NAFLD and Hepatic Fibrosis. PLoS One (2015) 0.75
Aliskiren and valsartan combination therapy for the management of hypertension. Vasc Health Risk Manag (2010) 0.75
Mineralocorticoid receptor deficiency in macrophages inhibits atherosclerosis by affecting foam cell formation and efferocytosis. J Biol Chem (2016) 0.75
Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med (1991) 16.19
Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med (2010) 14.43
Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med (2008) 11.61
Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial. Lancet (2012) 6.69
The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation (2006) 6.58
Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med (2014) 5.93
Long-term air pollution exposure and acceleration of atherosclerosis and vascular inflammation in an animal model. JAMA (2005) 5.83
Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol (2003) 3.09
Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure. Circulation (2005) 2.85
Effects of a new hormone therapy, drospirenone and 17-beta-estradiol, in postmenopausal women with hypertension. Hypertension (2006) 2.83
Altered tetrahydrobiopterin metabolism in atherosclerosis: implications for use of oxidized tetrahydrobiopterin analogues and thiol antioxidants. Arterioscler Thromb Vasc Biol (2002) 2.53
Cardiovascular events during differing hypertension therapies in patients with diabetes. J Am Coll Cardiol (2010) 2.43
The impact of the coronary collateral circulation on mortality: a meta-analysis. Eur Heart J (2011) 2.33
Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects. Insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) substudy. J Am Coll Cardiol (2011) 2.29
Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity. Nat Med (2007) 2.23
Prediction of mode of death in heart failure: the Seattle Heart Failure Model. Circulation (2007) 2.22
Implications of geographical variation on clinical outcomes of cardiovascular trials. Am Heart J (2012) 2.06
Effects of digoxin at low serum concentrations on mortality and hospitalization in heart failure: a propensity-matched study of the DIG trial. Int J Cardiol (2007) 2.05
A propensity-matched study of the association of low serum potassium levels and mortality in chronic heart failure. Eur Heart J (2007) 2.01
Molecular imaging of interstitial alterations in remodeling myocardium after myocardial infarction. J Am Coll Cardiol (2008) 1.97
Withdrawal of cerivastatin from the world market. Curr Control Trials Cardiovasc Med (2001) 1.88
Influence of baseline and worsening renal function on efficacy of spironolactone in patients With severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study). J Am Coll Cardiol (2012) 1.87
Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure). J Am Coll Cardiol (2013) 1.83
Effect of intensive versus standard blood pressure lowering on diastolic function in patients with uncontrolled hypertension and diastolic dysfunction. Hypertension (2009) 1.82
Medical costs and quality of life 10 to 12 years after randomization to angioplasty or bypass surgery for multivessel coronary artery disease. Circulation (2004) 1.73
The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. Arch Intern Med (2005) 1.72
Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study. J Am Coll Cardiol (2012) 1.71
Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analyses. Arch Intern Med (2004) 1.69
Serum potassium and outcomes in CKD: insights from the RRI-CKD cohort study. Clin J Am Soc Nephrol (2010) 1.69
Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis. Circ Heart Fail (2012) 1.67
Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail (2008) 1.65
Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circ Heart Fail (2012) 1.62
Diuretic use, progressive heart failure, and death in patients in the DIG study. J Card Fail (2006) 1.61
Molecular imaging for efficacy of pharmacologic intervention in myocardial remodeling. JACC Cardiovasc Imaging (2009) 1.61
Midcourse correction to a clinical trial when the event rate is underestimated: the Look AHEAD (Action for Health in Diabetes) Study. Clin Trials (2012) 1.54
Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: a hypertensive population at high cardiovascular risk. Blood Press (2007) 1.52
Renal outcomes in hypertensive Black patients at high cardiovascular risk. Kidney Int (2011) 1.51
Hypokalemia and outcomes in patients with chronic heart failure and chronic kidney disease: findings from propensity-matched studies. Circ Heart Fail (2010) 1.50
Effects of drospirenone/17-beta estradiol on blood pressure and potassium balance in hypertensive postmenopausal women. Am J Hypertens (2005) 1.49
Statin therapy and clinical outcomes in myocardial infarction patients complicated by acute heart failure: insights from the EPHESUS trial. Eur J Heart Fail (2012) 1.49
ACCF/AHA consensus conference report on professionalism and ethics. Circulation (2004) 1.47
Aldosterone blockade in patients with acute myocardial infarction. Circulation (2003) 1.45
Maximizing scientific knowledge from randomized clinical trials. Am Heart J (2010) 1.42
Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial. Circ Heart Fail (2013) 1.40
Effects of angiotensin-converting enzyme inhibition on transient ischemia: the Quinapril Anti-Ischemia and Symptoms of Angina Reduction (QUASAR) trial. J Am Coll Cardiol (2003) 1.39
Low-density lipoprotein cholesterol in patients with stable coronary heart disease--is it time to shift our goals? N Engl J Med (2005) 1.33
Selective survival of peripheral blood lymphocytes in children with HIV-1 following delivery of an anti-HIV gene to bone marrow CD34(+) cells. Mol Ther (2005) 1.28
Depression predicts mortality and hospitalization in patients with myocardial infarction complicated by heart failure. Am Heart J (2005) 1.27
Hyperuricaemia, chronic kidney disease, and outcomes in heart failure: potential mechanistic insights from epidemiological data. Eur Heart J (2011) 1.26
The human coronary collateral circulation: development and clinical importance. Eur Heart J (2013) 1.23
Neutral effect on markers of heart failure, inflammation, endothelial activation and function, and vagal tone after high-dose HMG-CoA reductase inhibition in non-diabetic patients with non-ischemic cardiomyopathy and average low-density lipoprotein level. J Am Coll Cardiol (2005) 1.22
Lithospheric structure of the Rio Grande rift. Nature (2005) 1.20
A survey of knowledge, attitudes, and beliefs of medical students concerning antimicrobial use and resistance. Microb Drug Resist (2010) 1.17
Systolic blood pressure and cardiovascular outcomes during treatment of hypertension. Am J Med (2013) 1.17
Exceptional early blood pressure control rates: the ACCOMPLISH trial. Blood Press (2007) 1.15
Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction. Circ Heart Fail (2010) 1.15
Effectiveness of digoxin in reducing one-year mortality in chronic heart failure in the Digitalis Investigation Group trial. Am J Cardiol (2008) 1.14
Haemoglobin predicts survival in patients with chronic heart failure: a substudy of the ELITE II trial. Eur Heart J (2004) 1.13
Chronic iron administration increases vascular oxidative stress and accelerates arterial thrombosis. Circulation (2003) 1.11
Cardiovascular safety of drugs not intended for cardiovascular use: need for a new conceptual basis for assessment and approval. Eur Heart J (2007) 1.09
Predictors of blood pressure response to intensified and fixed combination treatment of hypertension: the ACCOMPLISH study. Blood Press (2008) 1.08
Low serum magnesium and cardiovascular mortality in chronic heart failure: a propensity-matched study. Int J Cardiol (2008) 1.07
Eplerenone in patients with systolic heart failure and mild symptoms: analysis of repeat hospitalizations. Circulation (2012) 1.06
Heart failure as an endpoint in heart failure and non-heart failure cardiovascular clinical trials: the need for a consensus definition. Eur Heart J (2008) 1.05
Oral potassium supplement use and outcomes in chronic heart failure: a propensity-matched study. Int J Cardiol (2009) 1.02
Rationale and design of the Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure (EMPHASIS-HF). Eur J Heart Fail (2010) 1.02
Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. Eur Heart J (2012) 1.02
Mild hyperkalemia and outcomes in chronic heart failure: a propensity matched study. Int J Cardiol (2009) 1.01
GLUT4 facilitative glucose transporter specifically and differentially contributes to agonist-induced vascular reactivity in mouse aorta. Arterioscler Thromb Vasc Biol (2005) 1.01
Expanding the outcomes in clinical trials of heart failure: the quality of life and economic components of EPHESUS (EPlerenone's neuroHormonal Efficacy and SUrvival Study). Am Heart J (2002) 1.00
Association of obesity and survival in systolic heart failure after acute myocardial infarction: potential confounding by age. Eur J Heart Fail (2010) 0.99
Impact of diabetes mellitus on outcomes in patients with acute myocardial infarction and systolic heart failure. Eur J Heart Fail (2011) 0.99
A lifetime of prevention: the case of heart failure. Circulation (2002) 0.97
When to stop a clinical trial early for benefit: lessons learned and future approaches. Circ Heart Fail (2012) 0.95
Temporoparietal fascia flaps and superficial musculoaponeurotic system plication in parotid surgery reduces Frey's syndrome. J Oral Maxillofac Surg (2002) 0.94
Globalization of cardiovascular clinical research: the balance between meeting medical needs and maintaining scientific standards. Am Heart J (2007) 0.94
Decongestion in acute heart failure. Eur J Heart Fail (2014) 0.94
Learning from recent trials and shaping the future of acute heart failure trials. Am Heart J (2013) 0.92
ACE inhibitors for patients with vascular disease without left ventricular dysfunction--may they rest in PEACE? N Engl J Med (2004) 0.92
Biomarker-guided therapies in heart failure: a forum for unified strategies. J Card Fail (2013) 0.91
A history of systemic hypertension and incident heart failure hospitalization in patients with acute myocardial infarction and left ventricular systolic dysfunction. Am J Cardiol (2009) 0.91
Cyclooxygenase-2 inhibition and cardiovascular events. Circulation (2002) 0.91
Statin use and survival in patients with chronic heart failure--results from two observational studies with 5200 patients. Int J Cardiol (2006) 0.90
The past, present and future of renin-angiotensin aldosterone system inhibition. Int J Cardiol (2012) 0.90
Oxaliplatin toxicity masquerading as recurrent colon cancer. J Clin Oncol (2004) 0.89
The relationship between renal impairment and left ventricular structure, function, and ventricular-arterial interaction in hypertension. J Hypertens (2011) 0.89
PEARL-HF: prevention of hyperkalemia in patients with heart failure using a novel polymeric potassium binder, RLY5016. Future Cardiol (2012) 0.88
Effect of losartan in aging-related endothelial impairment. Am J Cardiol (2002) 0.88
Comparison of benazepril plus amlodipine or hydrochlorothiazide in high-risk patients with hypertension and coronary artery disease. Am J Cardiol (2013) 0.87
Comparison of losartan and captopril on heart failure-related outcomes and symptoms from the losartan heart failure survival study (ELITE II). Am Heart J (2005) 0.87
Cardiovascular protection for all individuals at high risk: evidence-based best practice. Clin Res Cardiol (2008) 0.86
The relationship between anemia, change in hematocrit over time and change in health status in patients with heart failure after myocardial infarction. J Card Fail (2008) 0.86